

11 October 2017

Companies Announcements Office  
ASX Limited

**Notice under Section 708AA of the Corporations Act 2001 (Cth)**

**Avita Medical Limited** ACN 058 466 523 (**Avita or the Company**), (ASX code: **AVH**) today announced a fully underwritten non-renounceable rights issue to 'Eligible Shareholders' on the basis of 1 fully paid ordinary share (**New Share**) for every 2.8 fully paid ordinary share held, at an issue price of \$0.045 per New Share to raise a maximum of \$12.44 million (before costs) by the issue of approximately 276.5 million Shares (**Rights Issue**).

The Company also announced that it has received commitments from sophisticated and professional investors to invest a total of a further \$4.5 million at the same price as under the Rights Issue (**Placement**).

Eligible shareholders are those shareholders who are, as at 5.00pm AEST time on the Record Date (being 18 October 2017), registered with a registered address situated in Australia and New Zealand.

In accordance with section 708AA(2)(f) of the *Corporations Act 2001 (Cth)* (**the Act**), the Company gives notice that:

- (a) The New Shares will be offered for issue without disclosure to investors under Part 6D.2 of the Act;
- (b) This notice is given by the Company under section 708AA(2)(f) of the Act;
- (c) As at the date of this notice, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (ii) section 674 of the Act;
- (d) As at the date of this notice, there is no information:
  - (i) that has been excluded from a continuous disclosure notice in accordance with the Listing Rules of ASX; and
  - (ii) that investors and their professional advisers would reasonably require, and would reasonably expect to find in a disclosure document, for the purpose of making an informed assessment of:
    - (A) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; and
    - (B) the rights and liabilities attaching to the New Shares.

(e) The issue of the New Shares may affect the control of the Company.

As the Rights Issue is underwritten by Bell Potter, the potential effect of the Rights Issue on the control of the Company is as follows:

<b>Issued Shares</b>	<b>Shares</b>
Total issued capital of the Company as at the Record Date (including Shares issued pursuant to the Placement)	774,219,854
Number of Shares offered under the Rights Issue (assuming maximum number of Shares are issued under the Rights Issue)	<u>276,500,000</u>
<b>Total Issued Capital of the Company at completion of the Rights Issue</b>	<b>1,050,719,854</b>

The above calculations assume that \$12.44 million New Shares are issued under the Rights Issue Offer. However, the exact number of New Shares to be issued pursuant to the Rights Issue Offer cannot be calculated until entitlements have been determined following the Record Date.

Investors should note the following:

- If particular eligible Shareholders do not take up all of their entitlements under the offer, the Share interests of those Shareholders will be diluted;
- The proportional interests of Shareholders with registered addresses outside Australia and New Zealand will be diluted because those Shareholders are not entitled to participate in the Rights Issue; and
- Should the Company's major Shareholders subscribe for their full entitlement under the Rights Issue, there will not be any material impact on the control of the Company following the issue of Shares under the Rights Issue.

For further details about the Rights Issue please refer to the capital raising announcement released to the ASX on 11 October 2017.

Yours faithfully



**Gabriel Chiappini**  
Company Secretary